|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
DE69739802D1
(de)
*
|
1996-07-24 |
2010-04-22 |
Celgene Corp |
Substituierte 2-(2,6-Dioxopiperidine-3-yl)-phthalimide -1-oxoisoindoline und Verfahren zur Reduzierung des TNF-alpha Spiegels
|
|
DE19703763C1
(de)
*
|
1997-02-01 |
1998-10-01 |
Gruenenthal Gmbh |
Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
|
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
DE69834668T2
(de)
*
|
1997-11-18 |
2007-01-11 |
Celgene Corp. |
Substituierte 2-(2,6-dioxo-3-fluoropiperidine-3-yl)-isoindoline und ihre Verwendung zum reduzieren des TNF-alpha spiegels
|
|
SK13642000A3
(sk)
*
|
1998-03-16 |
2001-04-09 |
Celgene Corporation |
2-(2,6-dioxopiperidin-3-yl)izoindolínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
|
|
WO2000055134A1
(en)
|
1999-03-18 |
2000-09-21 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
|
DE19917195B4
(de)
*
|
1999-04-16 |
2006-09-28 |
Immatics Biotechnologies Gmbh |
Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
PT1353672E
(pt)
*
|
2000-11-30 |
2008-01-11 |
Childrens Medical Center |
Síntese da 4-amino talidomida enantiómeros
|
|
EP1350792A1
(en)
*
|
2000-12-11 |
2003-10-08 |
Takeda Chemical Industries, Ltd. |
Medicinal compositions improved in solublity in water
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
DE60234585D1
(cg-RX-API-DMAC10.html)
|
2001-02-27 |
2010-01-14 |
Us Government |
|
|
CA2457319C
(en)
*
|
2001-08-06 |
2011-07-05 |
The Children's Medical Center Corporation |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
|
CN1981761B
(zh)
|
2002-05-17 |
2011-10-12 |
细胞基因公司 |
使用免疫调节性化合物用于制备治疗和控制癌症和其它疾病药物中的应用及组合物
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
|
FR2845994B1
(fr)
*
|
2002-10-18 |
2006-05-19 |
Servier Lab |
Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
JP2006507284A
(ja)
*
|
2002-10-24 |
2006-03-02 |
セルジーン・コーポレーション |
疼痛を治療、改変および管理するための免疫調節化合物の使用方法および組成物
|
|
JP2006508950A
(ja)
*
|
2002-10-31 |
2006-03-16 |
セルジーン・コーポレーション |
黄斑変性の治療用組成物
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
CH696542A5
(de)
*
|
2003-07-09 |
2007-07-31 |
Siegfried Ltd |
Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
|
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
|
WO2005028436A2
(en)
|
2003-09-17 |
2005-03-31 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
|
US7612096B2
(en)
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
|
EP1737453A4
(en)
|
2004-03-22 |
2008-11-26 |
Celgene Corp |
METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
|
|
MXPA06012648A
(es)
*
|
2004-05-05 |
2007-02-14 |
Celgene Corp |
Metodo de utilizacion y composiciones que comprenden compuestos inmunomodulatorios para el tratamiento y manejo de enfermedades mieloproliferativas.
|
|
MX2007002521A
(es)
*
|
2004-09-03 |
2007-05-09 |
Celgene Corp |
Procesos para la preparacion de 2-(2,6-dioxopiperidin-3-il)-1- oxoisoindolinas sustituidas.
|
|
SI2380887T1
(sl)
*
|
2005-06-30 |
2013-12-31 |
Celgene Corporation |
Postopki priprave spojin 4-amino-2-/2,6-dioksopiperidin-3-il)izoindolin -1,3-diona
|
|
US7928280B2
(en)
|
2005-07-13 |
2011-04-19 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
|
CN101291924A
(zh)
|
2005-08-31 |
2008-10-22 |
细胞基因公司 |
异吲哚-酰亚胺化合物和包含它们的组合物及其使用方法
|
|
ES2359162T3
(es)
|
2005-09-01 |
2011-05-19 |
Celgene Corporation |
Usos inmunologicos de compuestos inmunomoduladores para vacunas y terapia de enfermedades anti-infecciosas.
|
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物
|
|
KR20080097190A
(ko)
*
|
2005-12-29 |
2008-11-04 |
안트로제네시스 코포레이션 |
태반 줄기세포의 수집과 보존을 위한 개선된 조성물과 이조성물의 이용 방법
|
|
CA2646316C
(en)
|
2006-03-15 |
2016-05-24 |
Theralogics, Inc. |
Methods of treating muscular wasting diseases using nf-kb activation inhibitors
|
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
US8105634B2
(en)
|
2006-08-15 |
2012-01-31 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
|
EP2057143B1
(en)
*
|
2006-08-30 |
2013-07-24 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CN102898416A
(zh)
|
2006-09-26 |
2013-01-30 |
细胞基因公司 |
作为抗肿瘤剂的5-取代的喹唑酮衍生物
|
|
EP1923053A1
(en)
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
|
WO2008060377A2
(en)
|
2006-10-04 |
2008-05-22 |
Anthrogenesis Corporation |
Placental or umbilical cord tissue compositions
|
|
CA3178363A1
(en)
|
2006-10-06 |
2008-05-15 |
Celularity Inc. |
Human placental collagen compositions, and methods of making and using the same
|
|
US8492395B2
(en)
|
2007-09-26 |
2013-07-23 |
Celgene Corporation |
7-substituted quinazolinone compounds and compositions comprising the same
|
|
US20090088393A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Zomanex, Llc |
Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
|
|
KR20230065354A
(ko)
|
2007-09-28 |
2023-05-11 |
셀룰래리티 인코포레이티드 |
인간 태반 관류액 및 인간 태반-유래 중간체 천연 킬러 세포를 사용한 종양 억제 방법
|
|
US20090232776A1
(en)
*
|
2007-11-08 |
2009-09-17 |
Moutouh-De Parseval Laure A |
Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
|
|
EP2235213A2
(en)
|
2007-12-20 |
2010-10-06 |
Celgene Corporation |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
|
KR20100124710A
(ko)
*
|
2008-03-11 |
2010-11-29 |
닥터 레디스 레보러터리즈 리미티드 |
레날리도미드의 제조
|
|
US20110060010A1
(en)
*
|
2008-03-13 |
2011-03-10 |
Tianjin Hemay Bio-Tech Co., Ltd |
Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
|
|
CN101531653B
(zh)
*
|
2008-03-13 |
2014-07-09 |
峡江和美药业有限公司 |
3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
|
|
US20090298882A1
(en)
*
|
2008-05-13 |
2009-12-03 |
Muller George W |
Thioxoisoindoline compounds and compositions comprising and methods of using the same
|
|
SG195613A1
(en)
|
2008-10-29 |
2013-12-30 |
Celgene Corp |
Isoindoline compounds for use in the treatment of cancer
|
|
DE102008057284A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
|
|
DE102008057335A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Amorphes Lenalidomid
|
|
AU2009314568B2
(en)
*
|
2008-11-14 |
2016-01-21 |
Concert Pharmaceuticals Inc. |
Substituted dioxopiperidinyl phthalimide derivaties
|
|
DE102008057285A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
|
|
US9045453B2
(en)
|
2008-11-14 |
2015-06-02 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
US20120053159A1
(en)
|
2009-02-11 |
2012-03-01 |
Muller George W |
Isotopologues of lenalidomide
|
|
CA2756594C
(en)
|
2009-03-25 |
2021-03-23 |
Anthrogenesis Corporation |
Treatment of viral infection using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
|
SI3351240T1
(sl)
|
2009-05-19 |
2019-08-30 |
Celgene Corporation |
Formulacije 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
|
|
EP2436387B1
(en)
|
2009-05-25 |
2018-07-25 |
Celgene Corporation |
Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
|
|
CN101580501B
(zh)
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
|
CA2773012A1
(en)
|
2009-09-03 |
2011-03-10 |
Ranbaxy Laboratories Limited |
Process for the preparation of lenalidomide
|
|
WO2011050962A1
(en)
*
|
2009-10-29 |
2011-05-05 |
Ratiopharm Gmbh |
Acid addition salts of lenalidomide
|
|
CN102127054B
(zh)
*
|
2009-11-02 |
2013-04-03 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
|
CN101696205B
(zh)
|
2009-11-02 |
2011-10-19 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
|
WO2011069608A1
(en)
*
|
2009-12-09 |
2011-06-16 |
Ratiopharm Gmbh |
S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
|
|
SG181891A1
(en)
|
2009-12-22 |
2012-07-30 |
Celgene Corp |
(methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
|
EP4289838A3
(en)
|
2010-02-11 |
2024-03-13 |
Celgene Corporation |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
JP5937060B2
(ja)
|
2010-04-07 |
2016-06-22 |
セルジーン コーポレイション |
呼吸器ウイルス感染症の治療方法
|
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
US8853175B2
(en)
|
2011-01-10 |
2014-10-07 |
Celgene Corporation |
Phenethylsulfone isoindoline derivatives and their use
|
|
SG192946A1
(en)
|
2011-03-11 |
2013-09-30 |
Celgene Corp |
Solid forms of 3-(5-amino-2methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
|
US9090585B2
(en)
|
2011-03-28 |
2015-07-28 |
Deuterx, Llc |
2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
|
|
US20140106390A1
(en)
|
2011-04-18 |
2014-04-17 |
Celgene Corporation |
Biomarkers for the treatment of multiple myeloma
|
|
CA2834535A1
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
RU2017121896A
(ru)
|
2011-09-14 |
2019-01-29 |
Селджин Корпорейшн |
Препараты { 2-[(1s)-1-(3-этокси-4-метоксифенил)-2-метансульфонилэтил]-3-оксо-2,3-дигидро-1h-изоиндол-4-ил} амида циклопропанкарбоновой кислоты
|
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
|
CA2861594A1
(en)
|
2011-12-27 |
2013-07-04 |
Celgene Corporation |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
|
|
WO2013126394A1
(en)
*
|
2012-02-21 |
2013-08-29 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
AU2013273483A1
(en)
|
2012-06-06 |
2014-12-11 |
Bionor Immuno As |
Vaccine
|
|
EP3904875B1
(en)
|
2012-06-29 |
2024-11-20 |
Celgene Corporation |
Methods for determining drug efficacy using ikzf3 (aiolos)
|
|
EP3950681A3
(en)
|
2012-08-09 |
2022-04-13 |
Celgene Corporation |
Salts and solid forms of the compound (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
WO2014066243A1
(en)
|
2012-10-22 |
2014-05-01 |
Concert Pharmaceuticals, Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
FR2999915B1
(fr)
*
|
2012-12-21 |
2017-08-11 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique en tant qu'agent apaisant
|
|
FR2999914B1
(fr)
*
|
2012-12-21 |
2015-08-07 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement
|
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
|
US9540340B2
(en)
|
2013-01-14 |
2017-01-10 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
|
|
US9763983B2
(en)
|
2013-02-05 |
2017-09-19 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
|
EP3831840A1
(en)
|
2013-03-15 |
2021-06-09 |
Celgene Corporation |
Modified t lymphocytes
|
|
CN104072476B
(zh)
*
|
2013-03-27 |
2018-08-21 |
江苏豪森药业集团有限公司 |
泊马度胺晶型及其制备方法和用途
|
|
KR102223060B1
(ko)
|
2013-04-17 |
2021-03-05 |
시그날 파마소티칼 엘엘씨 |
암 치료를 위한 TOR 키나제 억제제 및 ＩＭｉＤ 화합물을 포함하는 조합요법
|
|
EP2815749A1
(en)
*
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
|
CN103497174B
(zh)
*
|
2013-07-29 |
2015-10-28 |
杭州派臣医药科技有限公司 |
泊利度胺的制备和精制方法
|
|
CN104557858B
(zh)
*
|
2013-10-29 |
2018-06-01 |
上海医药工业研究院 |
一种泊利度胺的制备方法
|
|
CN104557857A
(zh)
*
|
2013-10-29 |
2015-04-29 |
上海医药工业研究院 |
一种泊利度胺的纯化方法
|
|
PE20161030A1
(es)
|
2013-12-03 |
2016-11-06 |
Acetylon Pharmaceuticals Inc |
Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
|
|
CN104016967A
(zh)
*
|
2014-04-04 |
2014-09-03 |
南京工业大学 |
一种泊利度胺的合成方法
|
|
KR20220101015A
(ko)
*
|
2014-04-14 |
2022-07-18 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
|
CN105348257A
(zh)
*
|
2014-08-20 |
2016-02-24 |
河北菲尼斯生物技术有限公司 |
泊马度胺的制备方法
|
|
US10034872B2
(en)
|
2014-08-22 |
2018-07-31 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
CN105440013B
(zh)
*
|
2014-08-29 |
2018-10-09 |
杭州和泽医药科技有限公司 |
一种泊马度胺的制备方法
|
|
ES2901509T3
(es)
*
|
2014-10-30 |
2022-03-22 |
Kangpu Biopharmaceuticals Ltd |
Derivado de isoindolina, compuesto intermedio, métodos de preparación, composición farmacéutica y uso del mismo
|
|
US10507204B2
(en)
|
2014-12-19 |
2019-12-17 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
|
EP3233082B1
(en)
|
2014-12-19 |
2018-12-05 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
|
CN104447689B
(zh)
*
|
2014-12-22 |
2016-07-20 |
上海迈柏医药科技有限公司 |
来那度胺的晶型及其制备方法
|
|
WO2016118666A1
(en)
|
2015-01-20 |
2016-07-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of the androgen receptor
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
CN107787320B
(zh)
*
|
2015-05-22 |
2020-12-04 |
拜欧赛里克斯公司 |
靶向蛋白质的化合物、其组合物、方法和用途
|
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
WO2016210262A1
(en)
|
2015-06-26 |
2016-12-29 |
Celgene Corporation |
Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
|
WO2017030814A1
(en)
|
2015-08-19 |
2017-02-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
EP3393457A1
(en)
|
2015-12-22 |
2018-10-31 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
|
|
WO2017117118A1
(en)
|
2015-12-28 |
2017-07-06 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
|
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
ES2945224T3
(es)
|
2016-10-11 |
2023-06-29 |
Arvinas Operations Inc |
Compuestos y métodos para la degradación dirigida del receptor de andrógenos
|
|
KR102570992B1
(ko)
|
2016-11-01 |
2023-08-28 |
아비나스 오퍼레이션스, 인코포레이티드 |
타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법
|
|
CN110291087B
(zh)
|
2016-12-01 |
2024-07-09 |
阿尔维纳斯运营股份有限公司 |
作为雌激素受体降解剂的四氢萘和四氢异喹啉衍生物
|
|
KR20190104529A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포의 조절 방법
|
|
DK3527210T3
(da)
|
2016-12-16 |
2021-08-09 |
Kangpu Biopharmaceuticals Inc |
Kombineret sammensætning omfattende en benzoheterocyklisk forbindelse og en androgenreceptorvejsmodulator samt anvendelser deraf
|
|
WO2018119441A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Egfr proteolysis targeting chimeric molecules and associated methods of use
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
US10723717B2
(en)
|
2016-12-23 |
2020-07-28 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides
|
|
EP3559006A4
(en)
|
2016-12-23 |
2021-03-03 |
Arvinas Operations, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF F TAL LIVER KINASE POLYPEPTIDES
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
US10604506B2
(en)
|
2017-01-26 |
2020-03-31 |
Arvinas Operations, Inc. |
Modulators of estrogen receptor proteolysis and associated methods of use
|
|
IL312367A
(en)
|
2017-01-31 |
2024-06-01 |
Arvinas Operations Inc |
Cereblon ligands and bifunctional compounds comprising the same
|
|
CA3053805C
(en)
|
2017-02-13 |
2020-06-30 |
Kangpu Biopharmaceuticals, Ltd. |
Combination treating prostate cancer, pharmaceutical composition and treatment method
|
|
KR20240139092A
(ko)
|
2017-05-01 |
2024-09-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 요법 및 면역조절 화합물의 조합
|
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
|
WO2018223101A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
|
CN111050545A
(zh)
|
2017-06-29 |
2020-04-21 |
朱诺治疗学股份有限公司 |
评估与免疫疗法相关的毒性的小鼠模型
|
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
|
CN111511370A
(zh)
|
2017-11-01 |
2020-08-07 |
朱诺治疗学股份有限公司 |
对b细胞成熟抗原具有特异性的抗体和嵌合抗原受体
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
EP3710443A1
(en)
|
2017-11-17 |
2020-09-23 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
EP3724225A1
(en)
|
2017-12-15 |
2020-10-21 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
|
EP3505158A1
(en)
|
2017-12-27 |
2019-07-03 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
|
|
US11452722B2
(en)
|
2018-01-11 |
2022-09-27 |
Natco Pharma Limited |
Stable pharmaceutical compositions comprising lenalidomide
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
US11401336B2
(en)
|
2018-02-21 |
2022-08-02 |
Celgene Corporation |
BCMA-binding antibodies and uses thereof
|
|
EP3545949A1
(en)
|
2018-03-29 |
2019-10-02 |
Midas Pharma GmbH |
Oral dosage forms comprising pomalidomide crystalline form a
|
|
CN112218859B
(zh)
|
2018-04-04 |
2024-10-29 |
阿尔维纳斯运营股份有限公司 |
蛋白水解调节剂及相关使用方法
|
|
JP7581052B2
(ja)
|
2018-04-13 |
2024-11-12 |
サムヤン ホールディングス コーポレイション |
レナリドミドの経口用コーティング錠剤組成物
|
|
WO2019199132A1
(ko)
|
2018-04-13 |
2019-10-17 |
주식회사 삼양바이오팜 |
다양한 용량의 레날리도마이드의 경구용 정제 조성물
|
|
KR102286500B1
(ko)
|
2018-04-13 |
2021-08-05 |
주식회사 삼양홀딩스 |
레날리도마이드를 포함하는 경구용 고형제제의 제조방법
|
|
WO2019199134A1
(ko)
|
2018-04-13 |
2019-10-17 |
주식회사 삼양바이오팜 |
레날리도마이드를 포함하는 약제학적 조성물
|
|
KR102259798B1
(ko)
|
2018-04-13 |
2021-06-02 |
주식회사 삼양홀딩스 |
붕해가 개선된 레날리도마이드의 경구용 정제 조성물
|
|
CN112912376A
(zh)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
|
|
BR112021008930A2
(pt)
|
2018-11-08 |
2021-11-03 |
Juno Therapeutics Inc |
Métodos e combinações para o tratamento e modulação de célula t
|
|
CN113271963A
(zh)
|
2018-11-16 |
2021-08-17 |
朱诺治疗学股份有限公司 |
给予工程化t细胞以治疗b细胞恶性肿瘤的方法
|
|
CA3120869A1
(en)
|
2018-11-30 |
2020-06-04 |
Juno Therapeutics, Inc. |
Methods for treatment using adoptive cell therapy
|
|
US20230045737A1
(en)
*
|
2018-12-05 |
2023-02-09 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|
|
WO2020160050A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
|
US20230248696A1
(en)
*
|
2019-05-03 |
2023-08-10 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
|
CN110343063A
(zh)
*
|
2019-08-09 |
2019-10-18 |
新乡双鹭药业有限公司 |
一种泊马度胺合成中杂质的制备方法
|
|
KR20220054347A
(ko)
|
2019-08-26 |
2022-05-02 |
아비나스 오퍼레이션스, 인코포레이티드 |
에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
|
|
US11535606B2
(en)
|
2019-09-23 |
2022-12-27 |
Accutar Biotechnology Inc. |
Substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
|
US11420956B2
(en)
|
2019-09-23 |
2022-08-23 |
Accutar Biotechnology Inc. |
Ureas having Androgen Receptor degradation activity and uses thereof
|
|
JP2022552006A
(ja)
|
2019-10-17 |
2022-12-14 |
アルヴィナス・オペレーションズ・インコーポレイテッド |
Ｂｃｌ６標的化部分に連結されたｅ３ユビキチンリガーゼ結合部分を含有する二官能性分子
|
|
US11548870B2
(en)
|
2019-11-19 |
2023-01-10 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of helios protein
|
|
CN119039272A
(zh)
*
|
2019-12-17 |
2024-11-29 |
奥里尼斯生物科学股份有限公司 |
调节蛋白质募集和/或降解的化合物
|
|
CA3165168A1
(en)
|
2019-12-19 |
2021-06-24 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
MX2022012964A
(es)
|
2020-04-15 |
2022-11-09 |
Tecnimede Sociedade Tecnico Medicinal Sa |
Forma de dosificacion oral solida que comprende pomalidomida.
|
|
CA3181782A1
(en)
|
2020-05-09 |
2021-11-18 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
|
|
WO2022047145A1
(en)
|
2020-08-28 |
2022-03-03 |
Arvinas Operations, Inc. |
Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use
|
|
AR123492A1
(es)
|
2020-09-14 |
2022-12-07 |
Arvinas Operations Inc |
Formas cristalinas y amorfas de un compuesto para la degradación dirigida del receptor de estrógeno
|
|
WO2022152821A1
(en)
|
2021-01-13 |
2022-07-21 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
PE20231941A1
(es)
|
2021-04-06 |
2023-12-05 |
Bristol Myers Squibb Co |
Compuestos de oxoisoindolina sustituidos con piridinilo
|
|
MX2023011940A
(es)
|
2021-04-16 |
2023-12-07 |
Arvinas Operations Inc |
Moduladores de la proteolisis bcl6 y metodos de uso asociados.
|
|
WO2023126531A1
(en)
|
2021-12-31 |
2023-07-06 |
A Fine House S.A. |
Lenalidomide oral solution
|
|
EP4456875B1
(en)
|
2021-12-31 |
2025-10-15 |
a Fine House S.A. |
Oral solution comprising lenalidomide
|
|
KR20250029137A
(ko)
|
2022-06-22 |
2025-03-04 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Cd19-표적화된 car t 세포의 2차 요법을 위한 치료 방법
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
WO2024097905A1
(en)
|
2022-11-02 |
2024-05-10 |
Celgene Corporation |
Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
|
|
IL322247A
(en)
|
2023-01-26 |
2025-09-01 |
Arvinas Operations Inc |
Cerebellon-based KRAS-disrupting proteins and related uses
|
|
TW202535392A
(zh)
|
2023-12-08 |
2025-09-16 |
美商亞文納營運公司 |
使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮
|
|
WO2026006247A1
(en)
*
|
2024-06-26 |
2026-01-02 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
2-(piperidin-3-yl)isoindole-1,3-dione analogs and uses thereof
|